Considering that more than 50% of patients with EC are overweight or obese, and the expression of FAS is closely associated with the progression of EC, weight loss or targeting FAS can be proposed as a novel approach to treat or prevent the development of EC or to improve survival by reducing obesity-related comorbidities (17, 24–26). Here, FAS is linked to obesity due to melanocortin 4 receptor deficiency.